Latest News

Are you on an Infusion Treatment?

May 30, 2024 | Advocacy, Treatments

At MSNZ we would like to understand more about patient experiences with infusion treatments. The first line Disease Modifying Treatment (DMT) options we have been successful in advocating for in NZ are considered some of the best in the world. […]


Update – Ocrelizumab for Primary Progressive MS in Canterbury

May 29, 2024 | Life with MS, News, Progressive, Treatments

On Wednesday 15 May, Multiple Sclerosis NZ raised how critical workforce shortages are impacting patients with Primary Progressive MS (PPMS) access to time sensitive disease modifying therapies. A business case prepared by clinical specialists had been under review for five […]


Press Release: Access to Life-Changing MS Drug “snatched away” Due to Staff Shortages

May 15, 2024 | Advocacy, Funding, Life with MS, Media, News, Press Release, Treatments

A celebrated Pharmac decision late last year to fund a vital drug for many Multiple Sclerosis patients has fallen flat – with dozens being turned away for treatment due to severely stretched resources across a number of services. Multiple Sclerosis […]


Call for Pharmac to Widen Proposed Criteria for Shingrix Funding

February 29, 2024 | Advocacy, Treatments

Pharmac announced, in February, it was looking to extend funded access to Shingrix, the new vaccination for shingles, to immunocompromised people over 18 years old. However, the proposal listed specific treatments and conditions eligible. While we were pleased to see […]


Pharmax Sativex

February 29, 2024 | Treatments

In December 2023, Pharmac proposed to decline funding for inactive applications, this included an application to fund Sativex for MS spasticity. MSNZ has written to the Pharmac Board to ask that this application remain live and we be permitted to […]